Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin

2015263 citationsJournal Articlebronze Open Access

Authors

John P. Bilezikian · Columbia University

Nelson B. Watts · Mercy Health

Keith Usiskin · Janssen (United States)

David Polidori · Janssen (United States)

Albert Fung · Janssen (United States)

Daniel J. Sullivan · Janssen (United States)

Norm Rosenthal ·

Abstract

In older patients with T2DM, canagliflozin showed small but significant reductions in total hip BMD and increases in bone formation and resorption biomarkers, due at least in part to weight loss.

Topics & Keywords

Diabetes Treatment and Management Metabolism, Diabetes, and Cancer Pancreatitis Pathology and Treatment

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: The Journal of Clinical Endocrinology & Metabolism

Volume 101, Issue 1, pp. 44-51

DOI: 10.1210/jc.2015-1860

Field-Weighted Citation Impact: 21.68